South African case study sheds light on how vaccine manufacturing can be developed, Prof David Walwyn - The Conversation, April 2021

Posted on April 12, 2021

The uneven availability of COVID-19 vaccines has become an increasingly urgent and vexatious issue. But managing the problem of what’s been labelled “vaccine nationalism” is proving a hard nut to crack.

Shortages of medicines and vulnerable supply chains for critical medicines are issues for nearly all developing countries. In Africa, in particular, there’s limited manufacturing capacity. Over 20 countries don’t have any capacity at all. And many regions continue to import at least 95% of their pharmaceutical requirements.

Understanding why this is the case is key. After all, there is ample evidence that governments can be effective economic actors. This includes being able to exercise large influence on the manufacturing sector. They can, for example, build capacity through incentives, regulation and policy. Experiences from other countries show that public investment and public procurement in the domestic pharmaceutical sector can create capacity and markets.

So why hasn’t this happened on the continent?

Read more: South African case study sheds light on how vaccine manufacturing can be developed - The Conversation, 11 April 2021.

- Author Prof David Walwyn

Copyright © University of Pretoria 2024. All rights reserved.

COVID-19 Corona Virus South African Resource Portal

To contact the University during the COVID-19 lockdown, please send an email to [email protected]

FAQ's Email Us Virtual Campus Share Cookie Preferences